TXMD Files 8-K Furnishing Q2 2025 Earnings Press Release

Rhea-AI Filing Summary

TherapeuticsMD, Inc. disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02 via Item 7.01. The filing makes clear the material in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act and includes an explicit disclaimer that the company has no obligation to publicly update any forward-looking statements. The report lists the press release and an Inline XBRL cover page as exhibits.

Insights

Securities Analyst

Routine earnings disclosure; limited new information in the 8-K itself.

The company furnished a press release reporting its quarter-end results and designated it as Exhibit 99.1. Crucially, the filing specifies the press release is "furnished" rather than "filed," which is a standard distinction affecting incorporation-by-reference and certain liabilities. The document also reiterates the companys disclaimer that it has no obligation to update forward-looking statements. Because the 8-K does not contain the financial data itself, material analysis requires reviewing Exhibit 99.1.

Corporate Governance Expert

Standard Reg FD/8-K mechanics; procedural disclosure with governance-related disclaimer.

The filing follows routine disclosure practice by furnishing a press release under Item 7.01 and incorporating it into Item 2.02. It documents the exhibits, including the press release and an Inline XBRL cover page, and includes the companys explicit statement that the furnished information is not deemed filed. The disclaimer about not updating forward-looking statements is a typical governance/legal protection. The filing itself contains no operational or financial metrics; stakeholders should consult Exhibit 99.1 for substantive results.

false 0000025743 0000025743 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 12, 2025

THERAPEUTICSMD, INC. 

(Exact Name of Registrant as Specified in its Charter)

Nevada		001-00100		87-0233535
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

951 Yamato Road, Suite 220

Boca Raton, FL 33431

(Address of Principal Executive Office) (Zip Code)

Registrant’s telephone number, including area code: (561) 961-1900

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		TXMD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.

Item 7.01 Regulation FD Disclosure.

On August 12, 2025, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 and the information contained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Index

Exhibit No.		Description
99.1		Press Release from TherapeuticsMD, Inc., dated August 12, 2025, entitled “TherapeuticsMD Announces Second Quarter 2025 Financial Results.”
104		Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 12, 2025	THERAPEUTICSMD, INC.
	/s/ Marlan Walker
	Marlan Walker
	Chief Executive Officer

2

FAQ

What did TherapeuticsMD (TXMD) report in this 8-K?

The company furnished a press release announcing its financial results for the quarter ended June 30, 2025, provided as Exhibit 99.1.

Is the press release in the 8-K considered filed with the SEC?

No. The 8-K states that the information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed "filed" under the Exchange Act.

Where can I find the detailed financial results mentioned in this filing?

The detailed results are contained in the press release attached as Exhibit 99.1; the 8-K itself does not include the financial tables.

Does the company commit to updating forward-looking statements?

No. The filing expressly disclaims any obligation to release updates or changes to forward-looking statements or expectations.

What exhibits are listed in the 8-K?

The exhibit index lists Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Inline XBRL cover page tags).